163 related articles for article (PubMed ID: 2467958)
21. The monitoring of heparin activity during extracorporeal circulation.
Gomperts ED; Bethlehem B; Hockley J
S Afr Med J; 1977 Jun; 51(26):973-6. PubMed ID: 888033
[TBL] [Abstract][Full Text] [Related]
22. Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
Mittermayr M; Velik-Salchner C; Stalzer B; Margreiter J; Klingler A; Streif W; Fries D; Innerhofer P
Anesth Analg; 2009 Mar; 108(3):743-50. PubMed ID: 19224778
[TBL] [Abstract][Full Text] [Related]
23. [Control of the therapeutic heparin dosage in platelet rich citrate plasma after protamine neutralization].
Görss EW; Maercker W
Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):815-22. PubMed ID: 2436996
[TBL] [Abstract][Full Text] [Related]
24. [Factor Xa inhibitory assay to detect plasma heparin concentrations during and after cardiopulmonary bypass].
Wang L; Li L; Shi Y; Fang Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):310-2. PubMed ID: 12947723
[TBL] [Abstract][Full Text] [Related]
25. The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.
Esposito RA; Culliford AT; Colvin SB; Thomas SJ; Lackner H; Spencer FC
J Thorac Cardiovasc Surg; 1983 Feb; 85(2):174-85. PubMed ID: 6823136
[TBL] [Abstract][Full Text] [Related]
26. PEG-modified protamine with improved pharmacological/pharmaceutical properties as a potential protamine substitute: synthesis and in vitro evaluation.
Chang LC; Lee HF; Chung MJ; Yang VC
Bioconjug Chem; 2005; 16(1):147-55. PubMed ID: 15656586
[TBL] [Abstract][Full Text] [Related]
27. The determination of the heparin neutralising capacity of protamine using acridine orange fluorescence.
Edwards HE; Navaratnam S; Allen JC; Phillips GO
Thromb Haemost; 1980 Jun; 43(2):108-11. PubMed ID: 7455967
[TBL] [Abstract][Full Text] [Related]
28. Postoperative bleeding in cardiovascular surgery. Does heparin rebound really exist?
Gundry SR; Drongowski RA; Klein MD; Coran AG
Am Surg; 1989 Mar; 55(3):162-5. PubMed ID: 2919841
[TBL] [Abstract][Full Text] [Related]
29. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
30. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
[TBL] [Abstract][Full Text] [Related]
31. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
Mouton C; Calderon J; Janvier G; Vergnes MC
Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulant monitoring and neutralization during open heart surgery--a rapid method for measuring heparin and calculating safe reduced protamine doses.
Umlas J; Taff RH; Gauvin G; Swierk P
Anesth Analg; 1983 Dec; 62(12):1095-9. PubMed ID: 6650893
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
34. Reversal of protamine of the prolonged response to intrapulmonary heparin.
Wright CJ; Mahadoo J; Jaques LB
Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
[TBL] [Abstract][Full Text] [Related]
35. Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard.
Taneja R; Berry L; Pappu U; Stitt L; Sayal P; Allen P; Hoogendoorn H; Chan A
J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1227-32. PubMed ID: 25281041
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the hemodynamic and hematologic toxicity of a protamine variant after reversal of low-molecular-weight heparin anticoagulation in a canine model.
Hulin MS; Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Downing LJ; Stanley JC
Lab Anim Sci; 1997 Apr; 47(2):153-60. PubMed ID: 9150494
[TBL] [Abstract][Full Text] [Related]
38. Reversal of heparin after cardiac surgery: protamine titration using a statistical model.
Davidsson FÖ; Johagen D; Appelblad M; Svenmarker S
J Cardiothorac Vasc Anesth; 2015; 29(3):710-4. PubMed ID: 25813226
[TBL] [Abstract][Full Text] [Related]
39. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
[TBL] [Abstract][Full Text] [Related]
40. Heparin assay: a comparison between titrimetric and amidolytic methods.
Nenci GG; Berrettini M; Agnelli G; Parise P
Boll Soc Ital Biol Sper; 1980 Mar; 56(5):519-25. PubMed ID: 7387799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
